Elysium Neurological announces successful trial of Melo™ at Moorlands Neurological Centre

Elysium Neurological is delighted to announce the successful completion of a six-month trial of Melo™, a digital tool designed to streamline behavioural assessments.

Melo™ was introduced at the start of the year at Moorlands Neurological Centre in Staffordshire, a neurobehavioural hospital service for men and women over the age of 18 years, who have an acquired brain injury. 

The transdisciplinary team (TDT) used Melo™ to record OAS-MNR¹ and SASBA² data, which are standardised scales used in neurorehabilitation to assess and manage challenging behaviours. 

Professor Nick Alderman, Senior Clinical Director, Head of Psychology and Consultant Clinical Neuropsychologist at Elysium Neurological, said that Melo™ was bringing great improvements in understanding the effectiveness of treatments and the impact on the patient.

Nick said: “When using a paper-based system there are challenges to collecting the data, entering the data and then using the data to support the rehabilitation for the patient. Now that we are using Melo™, we see visualisation of that data instantly and we can see how that behaviour changes over time. 

“Most importantly if we have devised an implementation plan and we’ve put a treatment in place then we can see from the data whether it is having the desired effect and whether the challenging behaviour is reducing.”

Psychology Assistant, Isabelle Ellis, who had been supporting the team at Moorlands to begin using Melo™ whilst providing care, said that the behavioural management platform was positively impacting the whole team. 

Isabelle said: “It's much quicker now for the staff member to input the OAS-MNR and SASBA data and it is much quicker for the psychology team to analyse that data - Melo™ gives us the graphs straight away. We’ve received really positive feedback from the team and team members have said they feel empowered to be able to see the data themselves as well.”

Professor Nick Alderman shared this sentiment and said: “Melo™ can give us the gift of time – we want to free clinicians up as much as possible, to spend that time working with the patients, and that is what it is all about at the end of the day.”

James Chapman, Cofounder and Product Director at Melo™ said: “We’re incredibly proud to have partnered with the team at Moorlands over the past year - first to deeply understand the clinical opportunities for Melo™, and then to co-create and implement the platform in a way that truly fits their needs.

"This ongoing collaboration with the clinical teams has laid strong foundations for future work together. We’re excited to now be live at Avalon too, with over 5,000 assessments completed across Elysium Neurological sites to date.”

Footnotes

1. Overt Aggression Scale - Modified for Neurorehabilitation

2. St Andrew's Sexual Behaviour Assessment

Get the latest insights, blogs and news from Elysium Neurological over on their EveryExpert thought leadership hub: https://www.elysiumhealthcare.co.uk/neurological/every-expert/